Depression - Major Depressive DisorderDUAL MODNCT07879924
Dual Neuromodulation for Depression: Boosting TMS With tES
A study testing Transcranial Magnetic Stimulation and Transcranial Alternating Current Stimulation in people with Depression - Major Depressive Disorder, run by Mersey Care NHS Trust at 2 sites in United Kingdom.
Trial summary
Major depressive disorder (MDD) is a common and disabling condition. Transcranial magnetic stimulation (TMS) is an established non-invasive neuromodulation treatment for depression, but clinical response varies considerably between individuals. Read more about this study
- Who is it for?
- Ages 18 to 59 years
- Conditions the study is for
- Depression - Major Depressive Disorder
- What is being tested?
- Transcranial Magnetic Stimulation and Transcranial Alternating Current Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- Sep 2026to Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 59 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adults aged 18-59 years old inclusive
- Able to read and understand English
- Capacity to provide informed consent to the study
- PHQ-9 (Patient Health Questionnaire) score of 10-19 at screening
- Meets criteria for a current major depressive episode (standardised SCID-RV interview)
- Consents to researchers informing GP (and, if relevant, Local Mental Health Team) of study involvement
Who cannot join
- Currently under, or in need of, the care of mental health crisis (intensive home treatment) services
- Current mood disorder with psychotic features (SCID-5-RV interview)
- Current or past diagnosis of bipolar disorder, psychotic disorder, dementia, or mild cognitive impairment, or in the last twelve months alcohol/substance use disorder (SCID-5-RV interview)
- PHQ-9 suicide item score of greater than one
- MADRS suicide item score of greater than three
- Diagnosis of epilepsy or previous seizures or suspected seizures (other than seizures associated with fever with none beyond age five)
Show all 16Show fewer
- Active significant skin conditions affecting the scalp, forehead or behind the ears (e.g. psoriasis)
- Current known hearing problems or tinnitus
- Cochlear implants, neurostimulators, pacemaker, intracardiac lines, infusion devices
- Unremovable metal on head, neck or scalp (including unremovable hair extensions that contain metal, metallic piercings or red/orange/pink/yellow tattoos which may contain ferromagnetic dyes), or potential metal fragments in eyes
- Known or suspected pregnancy (if, on the day, a participant is unsure, they will be given the option to rebook the testing session or to conduct a urine pregnancy test - however, they will be advised that pregnancy tests are only accurate from the first day of a missed period)
- Medications judged to carry a significant increased risk of seizures
- Allergies to substances in the tACS paste
- Major unstable medical illness requiring further investigation or treatment
- Changes in psychoactive medications in the two weeks preceding screening
- Involvement in another clinical trial in the past three months, or current involvement in research study or trial that involves an intervention (medication, neuromodulation, psychotherapy)
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom2 sites
Mersey Care Mood Clinic at Knowsley Resource and Recovery Centre
Liverpool, L35 5DR
Jade Thai, +44 151 351 8858, jade.thai@merseycare.nhs.uk
Yue Peng
Mersey Care Mood Clinic at Knowsley Resource and Recovery Centre
Liverpool, L35 5DR
Yue Peng
About this study
Official title: Developing an Approach for Boosting the Effects of Transcranial Magnetic Stimulation in Major Depressive Disorder Using Synchronised Transcranial Electrical Stimulation ("tsTMS")
Major depressive disorder (MDD) is a common and disabling condition. Transcranial magnetic stimulation (TMS) is an established non-invasive neuromodulation treatment for depression, but clinical response varies considerably between individuals. One possible reason for this variability is that the effects of TMS may depend on the pattern of ongoing brain activity at the time stimulation is delivered.
This mechanistic, randomised, single-blind study will investigate whether synchronising TMS with transcranial alternating current stimulation (tACS), a form of weak electrical brain stimulation, can enhance the neurophysiological and cognitive effects of TMS in people experiencing a current moderate major depressive episode. The combined intervention is referred to as synchronised TMS (tsTMS).
Read more
Up to 60 participants will be recruited and randomised in a 1:1:1 ratio to one of three groups: (1) TMS synchronised to the peak of a theta-frequency tACS waveform, (2) TMS synchronised to the trough of a theta-frequency tACS waveform, or (3) TMS combined with sham tACS. Participants will receive five daily neuromodulation sessions over one week.
The primary objective is to estimate variability in change in emotional processing, measured using the Cambridge Cognition Emotional Bias Task, in order to inform the design and sample size calculation of a future clinical trial. The study will also assess participant acceptability and tolerability of the intervention. Secondary objectives include exploring changes in brain oscillatory activity measured using electroencephalography (EEG), cognitive performance, mood and anxiety symptoms, functional outcomes, and digital biomarkers collected from an optional wearable device.
This study is designed to investigate mechanisms and feasibility rather than provide a full therapeutic course of TMS. Findings will be used to inform the development of a future definitive clinical trial evaluating whether synchronised neuromodulation can improve outcomes in depression.
- Conditions
- Depression - Major Depressive Disorder
- Being tested
- Transcranial Magnetic Stimulation, Transcranial Alternating Current Stimulation
- Keywords
- Transcranial Magnetic Stimulation, TMS, Major Depressive Disorder, MDD, Depression, Neuromodulation, Transcranial Alternating Current Stimulation, tACS
- Medical subject headings
- Depressive Disorder, Major, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcranial Magnetic StimulationDevice
Also called TMS
Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation intervention delivered using a magnetic coil positioned over the scalp to generate brief magnetic pulses that stimulate targeted cortical brain regions.
Transcranial Alternating Current StimulationDevice
Also called tACS
Transcranial Alternating Current Stimulation (tACS) is a non-invasive neuromodulation intervention that delivers a weak alternating electrical current through electrodes placed on the scalp to modulate neural oscillatory activity in targeted brain regions.
| Study group | Role | What they receive |
|---|---|---|
| Peak synchronising TMS to tACS (tsTMS-p) | Experimental | Not described Receives: Device: Transcranial Magnetic Stimulation; Device: Transcranial Alternating Current Stimulation |
| Trough synchronising TMS to tACS (tsTMS-t) | Experimental | Not described Receives: Device: Transcranial Magnetic Stimulation; Device: Transcranial Alternating Current Stimulation |
| TMS with sham tACS | Placebo comparator | Not described Receives: Device: Transcranial Magnetic Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in emotional bias (Cambridge Neuropsychological Test Automated Battery (CANTAB) Emotional Bias task)
Difference in shift of emotional bias between participants who receive five sessions of tsTMS (tACS + TMS) and participants who receive TMS alone (the two forms of tsTMS under study will be individually compared to TMS).
Measured: First measured at the baseline session (28 days within the first stimulation session), then measured at the fifth stimulation session, and finally repeated at the follow-up session (within 7 days +/- 3 days after the final, fifth stimulation session)
Frequency of adverse effects and tolerability
Total adverse effects score derived from the participant-completed adverse effects questionnaire administered after each stimulation session. The total score combines the frequency and severity of reported adverse effects.
Measured: After each of the five stimulation sessions.
Participant experience and acceptability
Participant perceptions of the acceptability and experience of receiving tsTMS or TMS with sham tACS and of participating in the study, assessed through a semi-structured qualitative interview.
Measured: Follow-up visit within 7 days (±3 days) after the fifth stimulation session
Secondary outcomes (14)
Change in task-related theta-frequency brain oscillatory activity
Change in task-related theta-frequency brain oscillatory activity following neuromodulation, measured using electroencephalography (EEG). The outcome will compare changes in the fronto-midline theta activity during a working memory task between participants receiving tsTMS and those receiving TMS with sham tACS.
Measured: Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5 min and 30 min post-stimulation) within the same session.
Change in Frontal Theta Power
Change in resting-state frontal theta power measured using EEG during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.
Change in Central Beta Power
Change in resting-state central beta power measured using electroencephalogram (EEG) during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.
Change in Occipital Alpha Power
Change in resting-state occipital alpha power measured using EEG during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.
Change in Subjective Cognitive Difficulties (Perceived Deficits Questionnaire for Depression, 5-item version (PDQ-5-D))
Change in subjective cognitive difficulties from baseline to follow-up, assessed using the Perceived Deficits Questionnaire (PDQ-5-D). Changes following tsTMS will be compared with TMS with sham tACS.
Total scores range from 0 to 20, with higher scores indicating greater perceived cognitive difficulties and lower scores indicating better subjective cognitive functioning.
Measured: Baseline and follow-up visit (within 7 days ±3 days after the fifth stimulation session).
Change in Choice Reaction Time
Change in reaction time performance from baseline to follow-up, assessed using the THINC-it Choice Reaction Time task. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Baseline and follow-up visit (within 7 days ± 3 days after the fifth stimulation session).
Change in Digit Symbol Substitution Test (DSST) Performance
Change in cognitive performance from baseline to follow-up, assessed using the Digit Symbol Substitution Test (DSST). Changes following tsTMS will be compared with TMS with sham tACS.
The score is the total number of correct symbol-digit substitutions completed during the test period. Higher scores indicate better cognitive performance and faster processing speed, while lower scores indicate poorer performance.
Measured: Baseline and follow-up visit (within 7 days ± 3 days after the fifth stimulation session).
Change in Physical Activity Levels
Change in physical activity levels measured using the optional EmbracePlus wearable device. Activity metrics include actigraphy-derived activity measures and step count. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Gait Characteristics
Change in gait characteristics measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Sleep Metrics
Change in sleep-related measures recorded using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Pulse Rate
Change in pulse rate measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Skin Temperature
Change in skin temperature measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Electrodermal Activity
Change in electrodermal activity measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Respiratory Rate
Change in respiratory rate measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS.
Measured: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2026
- Study startSep 2026 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Depression - Major Depressive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mersey Care NHS Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07879924
- Sponsor's protocol ID
- 26/EE/0120
- Acronym
- DUAL MOD
- Status last verified
- Aug 2026
- First submitted
- 24 Aug 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) collected during this study will not be made available to other researchers due to participant confidentiality, consent limitations, and data governance requirements.
Publications
Briley PM, Boutry C, Webster L, Veniero D, Harvey-Seutcheu C, Jung J, Liddle PF, Morriss R. Intermittent theta burst stimulation with synchronised transcranial alternating current stimulation leads to enhanced frontal theta oscillations and a positive shift in emotional bias. Imaging Neurosci (Camb). 2024 Jan 25;2:imag-2-00073. doi: 10.1162/imag_a_00073. eCollection 2024.
PubMed 40800403
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing an Approach for Boosting the Effects of Transcranial Magnetic Stimulation in Major Depressive Disorder Using Synchronised Transcranial Electrical Stimulation ("tsTMS")
- ClinicalTrials.gov ID
- NCT07879924
- Acronym / sponsor ID
- DUAL MOD / 26/EE/0120
- Conditions
- Depression - Major Depressive Disorder
- Keywords
- Transcranial Magnetic Stimulation, TMS, Major Depressive Disorder, MDD, Depression, Neuromodulation, Transcranial Alternating Current Stimulation, tACS
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Mersey Care NHS TrustUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 19 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Major depressive disorder (MDD) is a common and disabling condition. Transcranial magnetic stimulation (TMS) is an established non-invasive neuromodulation treatment for depression, but clinical response varies considerably between individuals. One possible reason for this variability is that the effects of TMS may depend on the pattern of ongoing brain activity at the time stimulation is delivered.
This mechanistic, randomised, single-blind study will investigate whether synchronising TMS with transcranial alternating current stimulation (tACS), a form of weak electrical brain stimulation, can enhance the neurophysiological and cognitive effects of TMS in people experiencing a current moderate major depressive episode. The combined intervention is referred to as synchronised TMS (tsTMS).
Up to 60 participants will be recruited and randomised in a 1:1:1 ratio to one of three groups: (1) TMS synchronised to the peak of a theta-frequency tACS waveform, (2) TMS synchronised to the trough of a theta-frequency tACS waveform, or (3) TMS combined with sham tACS. Participants will receive five daily neuromodulation sessions over one week.
The primary objective is to estimate variability in change in emotional processing, measured using the Cambridge Cognition Emotional Bias Task, in order to inform the design and sample size calculation of a future clinical trial. The study will also assess participant acceptability and tolerability of the intervention. Secondary objectives include exploring changes in brain oscillatory activity measured using electroencephalography (EEG), cognitive performance, mood and anxiety symptoms, functional outcomes, and digital biomarkers collected from an optional wearable device.
This study is designed to investigate mechanisms and feasibility rather than provide a full therapeutic course of TMS. Findings will be used to inform the development of a future definitive clinical trial evaluating whether synchronised neuromodulation can improve outcomes in depression.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Peak synchronising TMS to tACS (tsTMS-p) | Experimental | Device: Transcranial Magnetic Stimulation, Device: Transcranial Alternating Current Stimulation |
| Trough synchronising TMS to tACS (tsTMS-t) | Experimental | Device: Transcranial Magnetic Stimulation, Device: Transcranial Alternating Current Stimulation |
| TMS with sham tACS | Placebo comparator | Device: Transcranial Magnetic Stimulation |
Who may qualify
- Ages
- 18 to 59 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Adults aged 18-59 years old inclusive
- Able to read and understand English
- Capacity to provide informed consent to the study
- PHQ-9 (Patient Health Questionnaire) score of 10-19 at screening
- Meets criteria for a current major depressive episode (standardised SCID-RV interview)
Key exclusion criteria (16 listed)
- Currently under, or in need of, the care of mental health crisis (intensive home treatment) services
- Current mood disorder with psychotic features (SCID-5-RV interview)
- Current or past diagnosis of bipolar disorder, psychotic disorder, dementia, or mild cognitive impairment, or in the last twelve months alcohol/substance use disorder (SCID-5-RV interview)
- PHQ-9 suicide item score of greater than one
- MADRS suicide item score of greater than three
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcranial Magnetic StimulationAlso: TMSTranscranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation intervention delivered using a magnetic coil positioned over the scalp to generate brief magnetic pulses that stimulate targeted cortical brain regions. | Device | Peak synchronising TMS to tACS (tsTMS-p), TMS with sham tACS, Trough synchronising TMS to tACS (tsTMS-t) |
| Transcranial Alternating Current StimulationAlso: tACSTranscranial Alternating Current Stimulation (tACS) is a non-invasive neuromodulation intervention that delivers a weak alternating electrical current through electrodes placed on the scalp to modulate neural oscillatory activity in targeted brain regions. | Device | Peak synchronising TMS to tACS (tsTMS-p), Trough synchronising TMS to tACS (tsTMS-t) |
Primary outcome
Change in emotional bias (Cambridge Neuropsychological Test Automated Battery (CANTAB) Emotional Bias task)
Time frame: First measured at the baseline session (28 days within the first stimulation session), then measured at the fifth stimulation session, and finally repeated at the follow-up session (within 7 days +/- 3 days after the final, fifth stimulation session)
Difference in shift of emotional bias between participants who receive five sessions of tsTMS (tACS + TMS) and participants who receive TMS alone (the two forms of tsTMS under study will be individually compared to TMS).
Frequency of adverse effects and tolerability
Time frame: After each of the five stimulation sessions.
Total adverse effects score derived from the participant-completed adverse effects questionnaire administered after each stimulation session. The total score combines the frequency and severity of reported adverse effects.
Participant experience and acceptability
Time frame: Follow-up visit within 7 days (±3 days) after the fifth stimulation session
Participant perceptions of the acceptability and experience of receiving tsTMS or TMS with sham tACS and of participating in the study, assessed through a semi-structured qualitative interview.
14 secondary outcomes
Change in task-related theta-frequency brain oscillatory activity
Time frame: Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5 min and 30 min post-stimulation) within the same session.
Change in Frontal Theta Power
Time frame: Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.
Change in Central Beta Power
Time frame: Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.
Change in Occipital Alpha Power
Time frame: Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.
Change in Subjective Cognitive Difficulties (Perceived Deficits Questionnaire for Depression, 5-item version (PDQ-5-D))
Time frame: Baseline and follow-up visit (within 7 days ±3 days after the fifth stimulation session).
Change in Choice Reaction Time
Time frame: Baseline and follow-up visit (within 7 days ± 3 days after the fifth stimulation session).
Change in Digit Symbol Substitution Test (DSST) Performance
Time frame: Baseline and follow-up visit (within 7 days ± 3 days after the fifth stimulation session).
Change in Physical Activity Levels
Time frame: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Gait Characteristics
Time frame: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Sleep Metrics
Time frame: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Pulse Rate
Time frame: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Skin Temperature
Time frame: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Electrodermal Activity
Time frame: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Change in Respiratory Rate
Time frame: Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Background: PubMed 40800403Briley PM, Boutry C, Webster L, Veniero D, Harvey-Seutcheu C, Jung J, Liddle PF, Morriss R. Intermittent theta burst stimulation with synchronised transcranial alternating current stimulation leads to enhanced frontal theta oscillations and a positive shift in emotional bias. Imaging Neurosci (Camb). 2024 Jan 25;2:imag-2-00073. doi: 10.1162/imag_a_00073. eCollection 2024.
- Individual participant dataSharing planned: No. Individual participant data (IPD) collected during this study will not be made available to other researchers due to participant confidentiality, consent limitations, and data governance requirements.
Related trials for Depression - Major Depressive Disorder
RecruitingPhase 1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Depression, Major Depressive Disorder
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
RecruitingPhase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Major Depressive Disorder (MDD), Depression in Adults
RecruitingPhase 1/2
Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder
Major Depression, Healthy Participants
RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcranial Magnetic Stimulation and Transcranial Alternating Current Stimulation in people with Depression - Major Depressive Disorder, run by Mersey Care NHS Trust at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yue Peng (+44 151 351 8858, dualmod.contact@merseycare.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in emotional bias (Cambridge Neuropsychological Test Automated Battery (CANTAB) Emotional Bias task) (time frame: First measured at the baseline session (28 days within the first stimulation session), then measured at the fifth stimulation session, and finally repeated at the follow-up session (within 7 days +/- 3 days after the final, fifth stimulation session)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07879924, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026; AzTrials last refreshed its copy on 31 Oct 2026.